OSE Immunotherapeutics replaces CEO

Following a board decision to terminate the mandate of Alexis Vandier, France-based biotech OSE Immunotherapeutics (Euronext: OSE) has appointed Dr Nicholas Poirier as its chief executive, with immediate effect.

The company did not explain the decision to replace Mr Vandier, a former Ipsen executive who only took on the CEO post in July this year.

Throughout his career, Dr Poirier has demonstrated both his expertise as an international scientific leader, pioneering the discovery and development of innovative immunotherapies, and in-depth knowledge of the biotech sector through various strategic leadership roles. He has been instrumental in the development of OSE Immunotherapeutics, notably as the initiator of fve programs in the company's portfolio that are now in clinical stage. He also played a major role in the signature of four strategic pharmaceutical partnerships for OSE Immunotherapeutics.